Intellia Therapeutics Inc (USD)
NTLA
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range22.85 | 23.90
52-Wk Range- | -
Last Close23.51
Mkt Cap (m)1,380.99
Dividend yield-
ISINUS45826J1051
Volume2,461,463.00
Exchange VenueNAS

Company Profile

Intellia Therapeutics Inc is a gene editing company focused on the development of proprietary, potentially curative therapeutics utilizing a biological tool known as the CRISPR/Cas9 system.

Key Information
Price/Earning-
Price/Book3.93
Price/Sales23.38
P/CF-
Rev Growth (3 year avg)37.78
EPS Growth (3 year avg)-
Operating Margin % -246.78
Net Margin %-230.92
Return on Equity-36.34
Debt/Equity0.07

Documents

Prospectus
en 03/06/2020
Annual Report
en 31/12/2019

Please refer to the below issuer website for further documents.

https://www.intelliatx.com

Financials

Income Statement
USD201420152016201720182019
Revenue (m)-6.0416.4826.1230.4343.10
Operating Income (m)--13.41-32.16-69.56-90.87-106.37
Net Income (m)--12.40-31.63-67.54-85.34-99.53
Basic EPS--0.70-1.42-1.88-1.98-2.11
Avg. Diluted Shares Outstanding (m)-17.6622.2236.0143.0747.25
Balance Sheet
USD201420152016201720182019
Current Assets (m)10.1377.63281.31354.83324.98289.48
Non Current Assets (m)0.564.5117.6621.4122.3444.80
Total Assets (m)10.6982.14298.97376.24347.32334.28
Current Liabilities (m)2.3610.7030.7331.3640.5735.63
Total Liabilities (m)------
Total Equity (m)7.5767.36209.84300.60277.92269.88
Cash Flows
USD201420152016201720182019
Operating Cash Flows (m)--1.7636.11-65.28-61.26-103.24
Capital Expenditure (m)--2.55-6.17-10.09-6.36-6.79
Figures are quoted in USD unless stated otherwise
-
No change
$
23.51
Last Price